Molecular pathology

Acupath Laboratories and Test Today USA Unite Forces to Open Dozens of COVID-19 PCR Testing Sites Across the Northeast and Beyond

Retrieved on: 
Wednesday, May 19, 2021

b'PLAINVIEW, N.Y., May 19, 2021 (GLOBE NEWSWIRE) -- Acupath Laboratories, Inc., a leading provider of sub-specialized anatomic and molecular pathology services, today announced its partnership with Test Today USA, LLC, to provide mobile COVID-19 testing nationwide.

Key Points: 
  • b'PLAINVIEW, N.Y., May 19, 2021 (GLOBE NEWSWIRE) -- Acupath Laboratories, Inc., a leading provider of sub-specialized anatomic and molecular pathology services, today announced its partnership with Test Today USA, LLC, to provide mobile COVID-19 testing nationwide.
  • Test Today USA will soon load collection sites into its mapping tool, providing the ability to easily find a nearby COVID-19 testing location .
  • Partnering with Acupath is crucial to meeting the testing expectations of those we serve.
  • Acupath is accredited by the New York State Department of Health, the Joint Commission, and the College of American Pathologists.\n'

Association for Molecular Pathology and Association of Pathology Chairs Call on Congress to Pass the Verified Innovative Testing in American Laboratories (VITAL) Act

Retrieved on: 
Tuesday, May 18, 2021

and WILMINGTON, Del., May 18, 2021 /PRNewswire/ --The Association for Molecular Pathology (AMP) and the Association of Pathology Chairs (APC) commend U.S.

Key Points: 
  • and WILMINGTON, Del., May 18, 2021 /PRNewswire/ --The Association for Molecular Pathology (AMP) and the Association of Pathology Chairs (APC) commend U.S.
  • Senator Rand Paul (R-KY) for introducing legislation that would allow molecular pathology professionals to continue advancing and offering high-quality laboratory developed testing procedures (LDPs) for patient care.
  • This legislation would help eliminate the duplicative oversight process by clarifying the federal regulatory authority over LDPs and encouraging the modernization of CLIA.
  • "\nThe Association of Pathology Chairs (APC) is a non-profit society, founded in 1967, to serve and give voice to academic departments of pathology and laboratory medicine in North America.

Medical College of Wisconsin Streamlines Molecular Pathology Lab Processes with GenomOncology Pathology Workbench

Retrieved on: 
Thursday, April 22, 2021

b'CLEVELAND, April 22, 2021 /PRNewswire/ --The Medical College of Wisconsin (MCW) Genomic Sciences & Precision Medicine Center (GSPMC) Precision Medicine Lab (PML) is implementing the newest version of GenomOncology\'s (GO) Pathology Workbench to further strengthen the efficiencies of its molecular oncology offerings.\nMCW has utilized GO\'s Pathology Workbench tool since 2014 in order to streamline its molecular pathology lab processes.

Key Points: 
  • b'CLEVELAND, April 22, 2021 /PRNewswire/ --The Medical College of Wisconsin (MCW) Genomic Sciences & Precision Medicine Center (GSPMC) Precision Medicine Lab (PML) is implementing the newest version of GenomOncology\'s (GO) Pathology Workbench to further strengthen the efficiencies of its molecular oncology offerings.\nMCW has utilized GO\'s Pathology Workbench tool since 2014 in order to streamline its molecular pathology lab processes.
  • "Implementing these newest tertiary analysis tools in the lab also enables us to provide patients with a comprehensive list of treatment recommendations available.
  • "\n"The flexibility of GO\'s Pathology Workbench allows for institutions to efficiently add customizations and additional panels in order to better fit their current workflows.
  • More than 1,400 students are enrolled in MCW\'s medical school and graduate school programs in Milwaukee, Green Bay and Central Wisconsin.

New Association for Molecular Pathology Report Reignites Effort for Appropriate Reimbursement for Professional Analysis, Interpretation, and Reporting of Molecular Diagnostic Testing Procedures

Retrieved on: 
Tuesday, March 16, 2021

Molecular diagnostic services are currently provided by both physicians and qualified doctoral scientists with specialized training and experience.

Key Points: 
  • Molecular diagnostic services are currently provided by both physicians and qualified doctoral scientists with specialized training and experience.
  • Since 2011, AMP has been a leading advocate for appropriate reimbursement for qualified healthcare professionals who are providing high-quality molecular diagnostic services.
  • To read the full report on the Analysis of Professional Work Effort in Molecular Test Interpretation, please visit: https://www.amp.org/MDx_Survey_Report .
  • The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics.

Latest Association for Molecular Pathology Survey Findings Indicate Significant Decline in Molecular Testing for Cancer During COVID-19 Pandemic

Retrieved on: 
Tuesday, February 23, 2021

ROCKVILLE, Md., Feb. 23, 2021 /PRNewswire/ --The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today released the preliminary results of its " Molecular Testing for Cancer during COVID-19 " survey of clinical laboratories.

Key Points: 
  • ROCKVILLE, Md., Feb. 23, 2021 /PRNewswire/ --The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today released the preliminary results of its " Molecular Testing for Cancer during COVID-19 " survey of clinical laboratories.
  • The latest anonymous survey assessed how important components of molecular diagnostic testing for cancer, including testing volumes, laboratory operations, clinical trial testing, patient samples, and turnaround times, were affected by the COVID-19 pandemic.
  • Overall, 85% of respondents reported that molecular testing for cancer decreased during April-June 2020.
  • The results from this survey underscore the significant supply chain and staffing shortages that were reported in AMP's April and August SARS-CoV-2 molecular testing surveys and show that they reverberate to molecular diagnostic testing for cancer.

NovoPath's AP LIS Receives Frost & Sullivan Technology Leadership Award for its Advanced Features that Transform AP Laboratory Workflow

Retrieved on: 
Tuesday, February 9, 2021

The award is based on the company's strong overall performance in enabling laboratories to realize simplified workflows.

Key Points: 
  • The award is based on the company's strong overall performance in enabling laboratories to realize simplified workflows.
  • Additionally, the streamlined operations empower the Anatomic Pathology Lab to provide cost efficiencies, rapid test results and outstanding customer service.
  • By offering a comprehensive Anatomic Pathology Laboratory Information Systems (AP LIS) and by expanding to the molecular pathology and digital pathology laboratory solutions market, NovoPath offers a complete and configurable multidisciplinary platform.
  • "Overall, Frost & Sullivan believes that NovoPath's strategic partnerships with top healthcare service providers, modern technology, and solid brand equity in the AP ecosystem have positioned it as the AP LIS vendor of choice in the North American market.

ProPath Appoints Soft Tissue Tumor Expert, Julia A. Bridge, M.D., as Director of Cytogenetics and FISH

Retrieved on: 
Thursday, January 7, 2021

She will also be incorporating her testing expertise in bone/soft tissue tumors for ProPaths molecular pathology team.

Key Points: 
  • She will also be incorporating her testing expertise in bone/soft tissue tumors for ProPaths molecular pathology team.
  • We are thrilled to have Dr. Bridge join our team, said Cory A. Roberts, M.D., President, Chairman and CEO of ProPath.
  • She has a rare combination of expertise in both anatomic pathology and cytogenetics that make her an expert with an international consultative practice.
  • Led by a team of world-class physicians and scientists, ProPath routinely diagnoses cases from 45 states and several foreign countries.

Asuragen to Present at Association for Molecular Pathology (AMP) 2020 Annual Meeting

Retrieved on: 
Tuesday, November 10, 2020

Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, will host two corporate workshops and present multiple scientific posters highlighting their new and upcoming products at the 2020 Association for Molecular Pathology (AMP) Annual Meeting & Expo, held virtually from November 16-20.

Key Points: 
  • Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, will host two corporate workshops and present multiple scientific posters highlighting their new and upcoming products at the 2020 Association for Molecular Pathology (AMP) Annual Meeting & Expo, held virtually from November 16-20.
  • Asuragens corporate workshops will be available on-demand throughout the event and will highlight the newest additions to the companys rapidly growing portfolio.
  • The company will also have a virtual booth during the conference, providing visitors the opportunity to access additional product materials and live chat with Asuragen representatives.
  • Asuragen is a molecular diagnostic product company changing the way patients are treated in genetics and oncology.

Diaceutics Partners With Global EQA Providers to Implement Best-in-class Testing Standards

Retrieved on: 
Monday, September 28, 2020

Currently focused on the Canadian market, CPQA-AQCP is dedicated to monitoring and improving the proficiency of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) testing.

Key Points: 
  • Currently focused on the Canadian market, CPQA-AQCP is dedicated to monitoring and improving the proficiency of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) testing.
  • The organization is currently collaborating with Diaceutics on a project sponsoring the HER2 biomarker modules for gastric cancer.
  • UK-based EMQN CIC provides molecular genetics, molecular pathology, and technique-specific EQA schemes for the global molecular testing market.
  • NordiQC actively cooperates with all stakeholders being laboratories, industry and regulatory bodies to promote and establish standards for immunohistochemical precision testing.

PathGroup Selected by NIH to Become RADx Program “Mega-Lab” for COVID-19 Testing

Retrieved on: 
Wednesday, September 2, 2020

The RADxSM initiative supports the development, production scale-up, and deployment of accurate, rapid SARS-CoV-2 tests across the country.

Key Points: 
  • The RADxSM initiative supports the development, production scale-up, and deployment of accurate, rapid SARS-CoV-2 tests across the country.
  • PathGroup is proud to be selected by the NIH RADxSM initiative to expand our industry-leading testing with 24-hour turnaround times, bringing ultra-high throughput testing capacity from some of the worlds leading diagnostic manufacturers to our clinician partners and the patients we collectively serve.
  • Nashville-based PathGroup provides comprehensive COVID-19 testing services for hospitals, physician offices, state and local departments of health, employers, and school systems, including both molecular diagnostic and antibody testing.
  • Founded in 1965, PathGroup is a premier provider of anatomic, clinical and molecular pathology laboratory services in the United States.